#USA #Class Action #Berger Montague #Gaithersburg #Altimmune

Legal Action Looms for Altimmune Investors

In a significant move for investors of Altimmune, Inc. (NASDAQ: ALT), national plaintiffs' law firm Berger Montague PC has announced a class action lawsuit against the company. This legal action is particularly crucial for shareholders who purchased or acquired publicly traded securities of Altimmune during the period spanning from August 10, 2023, to June 25, 2025. The deadline for investors to seek appointment as lead plaintiff is set for October 6, 2025, making it imperative for affected shareholders to understand their rights and options available to them.

Overview of the Situation

Based in Gaithersburg, Maryland, Altimmune is a clinical-stage biopharmaceutical company that specializes in developing therapies primarily targeting obesity and liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH). A sense of optimism surrounded the company until June 26, 2025, when it publicized the results from its IMPACT Phase 2b trial of Pemvidutide, a drug aspiring to treat MASH. The trial's results were disappointing, indicating a failure to meet the primary endpoint of statistical significance in fibrosis reduction, which was a surprising turn given the optimistic forecasts from company management leading up to the announcement.

The Aftermath of the Announcement

On June 26, following the release of these trial results, Altimmune’s stock saw a dramatic decline, plummeting by 53.2% in a single day, with shares closing at $3.61 compared to $7.71 just the day prior. Such a drastic fall not only reflects the market's reaction to potentially misleading information but also signifies the potential financial losses incurred by investors. This situation has prompted Berger Montague to step in and represent the investors who may have been misled by the company’s statements regarding the efficacy of its treatments.

Investor Rights and Class Action Participation

For investors who acquired Altimmune securities accurately during the Class Period, engaging in this class action provides a route for potential recovery. The firm encourages investors not to hesitate in asserting their rights, especially given the looming deadline of October 6, 2025, for applying as a lead plaintiff representative. Interested parties can reach out for consultation directly through the contact information shared by Berger Montague.

About Berger Montague

Founded in 1970, Berger Montague has a rich history in representing both individual and institutional investors, gaining a reputation as pioneers in securities class action litigation. With a network of offices across multiple major U.S. cities and internationally, the firm has established itself as a stalwart for those seeking legal recourse in the financial markets.

As the situation unfolds, Altimmune investors are strongly advised to stay informed about their legal standing and any developments regarding this class action suit. Their financial decisions moving forward should be made in consideration of the company's recent performance and the pending lawsuit, making this a critical time for shareholders to act.
For further inquiries or to discuss potential legal representation regarding Altimmune, interested parties are urged to contact Andrew Abramowitz or Caitlin Adorni at Berger Montague directly via the provided emails or phone numbers.